GLP-1 Drugs Lower Risk of Low Calcium But Raise Risk of High Calcium in Large Real-World Study

GLP-1 receptor agonists reduced the risk of hypocalcemia by 51% (2.7% vs 5.5%, RR 0.49) but doubled the risk of hypercalcemia (2.3% vs 1.1%, RR 2.02) compared to matched controls. Tirzepatide showed the strongest effects, reducing hypocalcemia by 63% while increasing hypercalcemia by 85%. GLP-1 RA use was also associated with significantly reduced emergency visits (RR 0.57), hospitalizations (RR 0.40), cardiovascular events, and all-cause mortality (HR 0.27). The hypocalcemia-protective effect was most pronounced in the first 6 months.

Retrospective cohort study using the TriNetX Global Collaborative Network. 15,655 adults prescribed GLP-1R agonists were propensity-matched to 15,655 controls. Outcomes included hypocalcemia, hypercalcemia, emergency visits, hospitalizations, cardiovascular events, and all-cause mortality. Individual agent effects (tirzepatide, semaglutide, dulaglutide, liraglutide) were analyzed separately.

With millions of patients now taking GLP-1 drugs, understanding their full physiological impact is critical. This study reveals a previously poorly understood effect on calcium balance — protecting against low calcium while potentially raising it too high. This has important implications for patients with bone disorders, those on calcium supplements, or those at risk for hypercalcemia. The broader finding of dramatically reduced mortality and hospitalizations further supports these peptide drugs' wide-ranging benefits.

As GLP-1 drugs are prescribed to increasingly diverse patient populations, understanding their effects on systems beyond glucose and weight is essential. This study adds calcium homeostasis to the list of physiological processes significantly influenced by GLP-1 receptor agonism. It also reinforces the remarkable mortality and hospitalization benefits seen in previous cardiovascular outcome trials, now confirmed in real-world data.

As a retrospective observational study, causal relationships cannot be established. Propensity matching may not account for all confounding variables. The mechanism behind the calcium effects is not elucidated. The TriNetX database relies on diagnostic codes, which may not capture mild or subclinical calcium disturbances. The study did not assess bone mineral density or fracture risk.